文献速递免疫规划传染病防控与疫情报告

荷兰按医学风险状况分层的COVID-19相关住院疫苗有效性:检测阴性病例对照研究

Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study.
PubMed 文献 · Vaccine · 2024-04-29

在荷兰九家医院开展的检测阴性病例对照研究显示,Delta变异株流行期间,335例病例和277例对照中,初次接种和加强接种对COVID-19相关住院的疫苗有效性分别为78%(95%CI:65-86)和89%(95%CI:69-96)。合并两个研究期共700例病例和511例对照的数据,60岁及以上人群及患有恶性肿瘤、慢性心脏病或免疫受损状况的患者中,初次接种的疫苗有效性显著降低。

要点

  • Delta变异株流行期间,初次接种和加强接种对COVID-19相关住院的疫苗有效性分别为78%和89%。
  • 60岁及以上人群及患有恶性肿瘤、慢性心脏病或免疫受损状况的患者中,初次接种的疫苗有效性显著降低。
  • 作者认为,对于某些高风险群体,间接保护或其他保护措施可能具有额外重要性。

核心结论

  • Delta变异株流行期间,针对COVID-19相关住院的疫苗有效性为78%,加强接种后升至89%。
  • 在某些高风险群体中疫苗有效性较低,作者认为间接保护或其他保护措施可能具有额外重要性。

研究设计与样本

  • 2021年3月至7月及2021年10月至2022年1月,在荷兰九家医院开展的多中心检测阴性病例对照研究。
  • 纳入有资格接种COVID-19疫苗且因呼吸道症状住院的成年人;病例为入院前14天内或入院后48小时内SARS-CoV-2检测阳性者,对照为检测阴性者。
  • 采用逻辑回归计算疫苗有效性,校正日历周、性别、年龄、养老院居住状态和合并症。

主要发现

  • 2021年10月至2022年1月Delta变异株流行期间,纳入335例病例和277例对照;初次接种和加强接种的疫苗有效性分别为78%(95%CI:65-86)和89%(95%CI:69-96)。
  • 合并两个研究期共700例病例和511例对照的数据,60岁及以上人群及患有恶性肿瘤、慢性心脏病或免疫受损状况的患者中,初次接种的疫苗有效性显著降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Vaccination remains crucial in reducing COVID-19 hospitalizations and mitigating the strain on healthcare systems. We conducted a multicenter study to assess vaccine effectiveness (VE) of primary and booster vaccination against hospitalization and to identify subgroups with reduced VE. METHODS: From March to July 2021 and October 2021 to January 2022, a test-negative case-control study was conducted in nine Dutch hospitals. The study included adults eligible for COVID-19 vaccination who were hospitalized with respiratory symptoms. Cases tested positive for SARS-CoV-2 within 14 days prior to or 48 h after admission, while controls tested negative. Logistic regression was used to calculate VE, adjusting for calendar week, sex, age, nursing home residency and comorbidity. We explored COVID-19 case characteristics and whether there are subgroups with less effective protection by vaccination against COVID-19 hospitalization. RESULTS: Between October 2021 to January 2022, when the Delta variant was dominant, 335 cases and 277 controls were included. VE of primary and booster vaccination was 78 % (95 % CI: 65-86), and 89 % (95 % CI: 69-96), respectively. Using data from both study periods, including 700 cases and 511 controls, VE of primary vaccination was significantly reduced in those aged 60+ and patients with malignancy, chronic cardiac disease or an immunocompromising condition. CONCLUSION: Although VE against hospitalization was 78% and increased to 89% after boosting during the Delta-dominant study period, VE was lower in certain high risk groups, for which indirect protection or other protective measures might be of added importance.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Niessen FA, Bruijning-Verhagen PCJL, Bonten MJM, et al. Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands by medical risk condition: A test-negative case-control study. Vaccine. 2024. PMID: 38688804. doi:10.1016/j.vaccine.2024.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。